Nanomedical Diagnostics announced a partnership with Rogue Valley Microdevices to deliver their graphene-based biosensors, AGILE R100. The partnership between Nanomedical Diagnostics and Rogue Valley Microdevices will open the novel sensing technique to any pharmaceutical company seeking to characterize biomolecules quickly and easily.
The AGILE R100 is designed to provide biophysical data to pharmaceutical and biotherapeutics companies seeking more informed decisions earlier in the drug discovery process. However, the company also plans a significant impact on the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms.
Nanomedical Diagnostics will be at the 2017 American Chemistry Society National Meeting in San Francisco to present AGILE R100 and the unique graphene biosensor technology behind the platform.
In February 2016, Nanomedical Diagnostics launched its AGILE (Automatic Graphene Immunolinked Electronic) biosensor Early Access Development Kit test, and in December 2016 ND started shipping its graphene-based sensors and the AGILE R100 system which allows for real-time detection of small molecules - with no lower size limit.
